Back to Journals » OncoTargets and Therapy » Volume 11

Efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in the treatment of advanced NSCLC in the elderly

Authors Wu C, Li B, Sun G, Peng C, Xiang D

Received 17 May 2018

Accepted for publication 15 August 2018

Published 8 October 2018 Volume 2018:11 Pages 6617—6624

DOI https://doi.org/10.2147/OTT.S174457

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava


Chunrong Wu,1,* Bo Li,2,* Guiyin Sun,1 Chunfang Peng,1 Debing Xiang1

1Department of Oncology, Jiangjin Center Hospital of Chongqing, Jiangjin, China; 2Department of Cardiology, Jiangjin Center Hospital of Chongqing, Jiangjin, China

*These authors contributed equally to this work

Background: Advanced non-small-cell lung cancer (NSCLC) is a huge challenge for physicians. Traditional chemoradiotherapy is associated with high rates of toxicities, especially when treating gerontal patients. Our study was focused on investigating the safety and efficacy of permanent iodine-125 seed implantation and chemotherapy for the treatment of advanced NSCLC in the elderly.
Methods: Fifty elderly patients with stage III or IV NSCLC at our hospital from January 2011 to June 2017 were treated with the chemotherapy regimens (paclitaxel/cisplatin) and computed tomography (CT)-guided iodine-125 brachytherapy (group A), 50 patients who received chemotherapy consisting of paclitaxel and cisplatin only (group B) were matched-up with the patients in group A. The local response rate was evaluated by CT. Progression-free survival (PFS) and overall survival (OS) data were obtained through clinical follow-up.
Results: The patients were followed-up for 3–46 months. With a median follow-up time of 20 months, the OS and PFS were 20 months (95% CI: 19.09–20.90 months) vs 15 months (95% CI: 14.48–15.51 months) (P<0.05) and 13 months (95% CI: 11.96–14.04 months) vs 8 months (95% CI: 7.63–8.37 months) (P<0.05) in group A and group B, respectively. The symptoms of patients in group A were significantly relieved when compared with group B. Severe complications were not observed in either of the groups.
Conclusion: The combination of iodine-125 seed brachytherapy and chemotherapy is an effective and safe therapy and is superior to chemotherapy alone for advanced NSCLC in the elderly.

Keywords: iodine-125, brachytherapy, chemotherapy, elderly, NSCLC

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]